BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Nagano H, Mori M. miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2011;414:675-680. [PMID: 21982769 DOI: 10.1016/j.bbrc.2011.09.124] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Li F, Huang Y, Huang YY, Kuang YS, Wei YJ, Xiang L, Zhang XJ, Jia ZC, Jiang S, Li JY, Wan Y. MicroRNA-146a promotes IgE class switch in B cells via upregulating 14-3-3σ expression. Mol Immunol 2017;92:180-9. [PMID: 29101850 DOI: 10.1016/j.molimm.2017.10.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
2 Hou Z, Zhang J, Han Q, Su C, Qu J, Xu D, Zhang C, Tian Z. Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a. Sci Rep. 2016;6:26150. [PMID: 27210312 DOI: 10.1038/srep26150] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
3 Aravalli RN. Development of microRNA therapeutics for hepatocellular carcinoma. Diagnostics. 2013;3:170-191. [PMID: 26835673 DOI: 10.3390/diagnostics3010170] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
4 Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013;57:840-7. [PMID: 23081718 DOI: 10.1002/hep.26095] [Cited by in Crossref: 251] [Cited by in F6Publishing: 245] [Article Influence: 27.9] [Reference Citation Analysis]
5 Budhwani M, Mazzieri R, Dolcetti R. Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Front Oncol 2018;8:322. [PMID: 30186768 DOI: 10.3389/fonc.2018.00322] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 16.5] [Reference Citation Analysis]
6 Asukai K, Kawamoto K, Eguchi H, Konno M, Asai A, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Nishida N, Satoh T, Doki Y, Mori M, Ishii H. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Ann Surg Oncol 2017;24:2344-52. [PMID: 28560603 DOI: 10.1245/s10434-017-5871-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
7 Fiorucci G, Chiantore MV, Mangino G, Romeo G. MicroRNAs in virus-induced tumorigenesis and IFN system. Cytokine Growth Factor Rev 2015;26:183-94. [PMID: 25466647 DOI: 10.1016/j.cytogfr.2014.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
8 Finch ML, Marquardt JU, Yeoh GC, Callus BA. Regulation of microRNAs and their role in liver development, regeneration and disease. Int J Biochem Cell Biol. 2014; Apr 13. [Epub ahead of print]. [PMID: 24731940 DOI: 10.1016/j.biocel.2014.04.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
9 Asaoka T, Hernandez D, Tryphonopoulos P, Tekin A, Garcia J, Nishida S, Fan J, Beduschi T, Vianna R, Ruiz P. Clinical significance of intragraft miR-122 and -155 expression after liver transplantation: Intragraft expression of miRNA-122 and -155. Hepatol Res 2015;45:898-905. [DOI: 10.1111/hepr.12424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
10 He Y, Huang C, Sun X, Long XR, Lv XW, Li J. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal. 2012;24:1923-1930. [PMID: 22735812 DOI: 10.1016/j.cellsig.2012.06.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 10.5] [Reference Citation Analysis]
11 Liu HT, Fang L, Cheng YX, Sun Q. LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. Cancer Med 2016;5:3512-9. [PMID: 27794184 DOI: 10.1002/cam4.900] [Cited by in Crossref: 77] [Cited by in F6Publishing: 86] [Article Influence: 12.8] [Reference Citation Analysis]
12 Takiuchi D, Eguchi H, Nagano H, Iwagami Y, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Mori M, Doki Y. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 2013;13:517-23. [DOI: 10.1016/j.pan.2013.06.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
13 Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012;4:369-81. [DOI: 10.2217/epi.12.39] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
14 Yuan Y, Kasar S, Underbayev C, Vollenweider D, Salerno E, Kotenko SV, Raveche E. Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus. Mol Immunol 2012;52:61-70. [PMID: 22578383 DOI: 10.1016/j.molimm.2012.04.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
15 Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res 2013;33:162-70. [PMID: 23570382 DOI: 10.1089/jir.2012.0110] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 7.7] [Reference Citation Analysis]
16 Hong L, Han Y, Zhang H, Zhao Q, Wu K, Fan D. Drug resistance-related miRNAs in hepatocellular cancer. Expert Rev Gastroenterol Hepatol 2014;8:283-8. [PMID: 24502538 DOI: 10.1586/17474124.2014.881713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Wang L, Yue Y, Wang X, Jin H. Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncol Lett. 2015;10:3345-3353. [PMID: 26788134 DOI: 10.3892/ol.2015.3759] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
18 Anwar SL, Lehmann U. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J Clin Med. 2015;4:1631-1650. [PMID: 26295264 DOI: 10.3390/jcm4081631] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
19 Romano G, Kwong LN. Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Rev. 2018;37:45-53. [PMID: 29270700 DOI: 10.1007/s10555-017-9716-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
20 Kim DH, Chang MS, Yoon CJ, Middeldorp JM, Martinez OM, Byeon SJ, Rha SY, Kim SH, Kim YS, Woo JH. Epstein-Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells. Oncotarget 2016;7:82213-27. [PMID: 27438138 DOI: 10.18632/oncotarget.10511] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
21 Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol 2014; 20(24): 7894-7913 [PMID: 24976726 DOI: 10.3748/wjg.v20.i24.7894] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
22 Yokota Y, Noda T, Okumura Y, Kobayashi S, Iwagami Y, Yamada D, Tomimaru Y, Akita H, Gotoh K, Takeda Y, Tanemura M, Murakami T, Umeshita K, Doki Y, Eguchi H. Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells. Cancer Sci 2021;112:1275-88. [PMID: 33426736 DOI: 10.1111/cas.14807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Nagano H, Obi S, Hatano E, Kaneko S, Kanai F, Omata M, Tsuji A, Itamoto T, Yamamoto K, Tanaka M, Kubo S, Hirata K, Nakamura H, Tomimaru Y, Yamanaka T, Kojima S, Monden M. Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases: S-1 alone vs. S-1/IFN-α in HCC. Hepatol Res 2018;48:717-26. [DOI: 10.1111/hepr.13067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer. 2013;109:502-511. [PMID: 23799850 DOI: 10.1038/bjc.2013.320] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
25 Pang L, Lu J, Huang J, Xu C, Li H, Yuan G, Cheng X, Chen J. Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2. Oncol Lett 2017;14:7745-52. [PMID: 29344219 DOI: 10.3892/ol.2017.7242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
26 Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018;8:9227. [PMID: 29907753 DOI: 10.1038/s41598-018-27521-y] [Cited by in Crossref: 506] [Cited by in F6Publishing: 602] [Article Influence: 126.5] [Reference Citation Analysis]
27 Xing Y, Wang Z, Lu Z, Xia J, Xie Z, Jiao M, Liu R, Chu Y. MicroRNAs: immune modulators in cancer immunotherapy. Immunotherapy Advances 2021;1:ltab006. [DOI: 10.1093/immadv/ltab006] [Reference Citation Analysis]
28 Katsura Y, Wada H, Murakami M, Akita H, Hama N, Kawamoto K, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. Ann Surg Oncol 2013;20 Suppl 3:S517-26. [PMID: 23508585 DOI: 10.1245/s10434-013-2948-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
29 Park JH, Jeong GH, Lee KS, Lee KH, Suh JS, Eisenhut M, van der Vliet HJ, Kronbichler A, Stubbs B, Solmi M, Dragioti E, Koyanagi A, Shin JI, Gamerith G. Genetic variations in MicroRNA genes and cancer risk: A field synopsis and meta-analysis. Eur J Clin Invest 2020;50:e13203. [PMID: 31984489 DOI: 10.1111/eci.13203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Perra A, Plateroti M, Columbano A. T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair. Endocr Relat Cancer. 2016;23:R353-R369. [PMID: 27353037 DOI: 10.1530/erc-16-0152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
31 Li JF, Dai XP, Zhang W, Sun SH, Zeng Y, Zhao GY, Kou ZH, Guo Y, Yu H, Du LY, Jiang SB, Zhou YS. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. mBio 2015;6:e02459-14. [PMID: 25805734 DOI: 10.1128/mBio.02459-14] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
32 Mukai R, Tomimaru Y, Nagano H, Eguchi H, Mimori K, Tomokuni A, Asaoka T, Wada H, Kawamoto K, Marubashi S, Doki Y, Mori M. miR-615-3p expression level in bone marrow is associated with tumor recurrence in hepatocellular carcinoma. Mol Clin Oncol 2015;3:487-94. [PMID: 26137255 DOI: 10.3892/mco.2015.514] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
33 Zhang J, Wang Y, Zhen P, Luo X, Zhang C, Zhou L, Lu Y, Yang Y, Zhang W, Wan J. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. PLoS One. 2013;8:e54111. [PMID: 23359607 DOI: 10.1371/journal.pone.0054111] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
34 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
35 Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 2014;74:1320-34. [PMID: 25053345 DOI: 10.1002/pros.22848] [Cited by in Crossref: 115] [Cited by in F6Publishing: 117] [Article Influence: 14.4] [Reference Citation Analysis]
36 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem. 2013;46:946-952. [PMID: 23396165 DOI: 10.1016/j.clinbiochem] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
37 Zhang WJ, Wang H, Tong QX, Jie SH, Yang DL, Peng C. Involvement of TLR2-MyD88 in abnormal expression of miR-146a in peripheral blood monocytes of patients with chronic hepatitis C. J Huazhong Univ Sci Technolog Med Sci. 2015;35:219-224. [PMID: 25877355 DOI: 10.1007/s11596-015-1414-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
38 Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, Wada H, Kawamoto K, Eguchi H, Konno M, Ishii H, Umeshita K, Doki Y, Mori M. Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol 2014;21 Suppl 4:S591-600. [PMID: 24740829 DOI: 10.1245/s10434-014-3705-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
39 Zuo C, Qiu X, Liu N, Yang D, Xia M, Liu J, Wang X, Zhu H, Xie H, Dan H, Li Q, Wu Q, Burns M, Liu C. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma. Exp Cell Res 2015;333:316-26. [PMID: 25724899 DOI: 10.1016/j.yexcr.2015.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ding B, Lou W, Xu L, Fan W. Non-coding RNA in drug resistance of hepatocellular carcinoma. Biosci Rep 2018;38:BSR20180915. [PMID: 30224380 DOI: 10.1042/BSR20180915] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 12.5] [Reference Citation Analysis]
41 Qi JH, Wang J, Chen J, Shen F, Huang JT, Sen S, Zhou X, Liu SM. High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer 2014;14:643. [PMID: 25176041 DOI: 10.1186/1471-2407-14-643] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
42 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem 2013;46:946-52. [PMID: 23396165 DOI: 10.1016/j.clinbiochem.2013.01.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
43 Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z. miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. Cell Cycle. 2015;14:243-252. [PMID: 25607648 DOI: 10.4161/15384101.2014.977112] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
44 Zhu D, Hu B, Zhou Y, Sun X, Chen J, Chen L, Ji Z, Zhu J, Duan Y. microRNA-146a is involved in rSjP40-inhibited activation of LX-2 cells by targeting Smad4 expression. J Cell Biochem 2018;119:9249-53. [PMID: 29953648 DOI: 10.1002/jcb.27193] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Lv S, Sun B, Dai C, Shi R, Zhou X, Lv W, Zhong X, Wang R, Ma W. The Downregulation of MicroRNA-146a Modulates TGF-β Signaling Pathways Activity in Glioblastoma. Mol Neurobiol 2015;52:1257-62. [PMID: 25326894 DOI: 10.1007/s12035-014-8938-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
46 Yuan F, Zhang S, Xie W, Yang S, Lin T, Chen X. Effect and mechanism of miR-146a on malignant biological behaviors of lung adenocarcinoma cell line. Oncol Lett 2020;19:3643-52. [PMID: 32382320 DOI: 10.3892/ol.2020.11474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]